Cymbalta Dosage/Direction for Use

For oral use.
Major Depressive Episodes: The starting and recommended maintenance dose is 60 mg once daily with or without food.
Therapeutic response is usually seen after 2-4 weeks of treatment.
After consolidation of the antidepressive response, it is recommended to continue treatment for several months, in order to avoid relapse.
Diabetic Peripheral Neuropathic Pain: The starting and recommended maintenance dose is 60 mg daily with or without food.
Response to treatment should be evaluated after 2 months. In patients with inadequate initial response, additional response after this time is unlikely.
The therapeutic benefit should be reassessed regularly (at least every three months) (see Pharmacology: Pharmacodynamics under Actions).
Generalized Anxiety Disorder (GAD): The starting and recommended maintenance dose is 60 mg once daily with or without food.
Some patients may benefit from dosages above the recommended 60 mg once daily up to a maximum dose of 120 mg per day.
Fibromyalgia (FM) with Depression: The starting and recommended maintenance dose is 60 mg once daily with or without food.
Some patients may benefit from dosages above the recommended 60 mg once daily up to a maximum dose of 120 mg per day.
Chronic pain (CP): The starting and recommended maintenance dose is 60 mg once daily with or without food.
Some patients may benefit from dosages above the recommended 60 mg once daily up to a maximum dose of 120 mg per day.
Special Populations and General Information: Hepatic impairment: CYMBALTA should not be used in patients with liver disease resulting in hepatic impairment (see Contraindications and Pharmacology: Pharmacokinetics under Actions).
Renal insufficiency: No dosage adjustment is necessary for patients with mild or moderate renal dysfunction (creatinine clearance 30 to 80 ml/min). See Contraindications for severe renal impairment.
Elderly: Major Depressive Episodes: No dosage adjustment is recommended for elderly patients solely on the basis of age. However, as with any medicine, caution should be exercised when treating the elderly, especially with CYMBALTA 120 mg per day for which data are limited (see Precautions and Pharmacology: Pharmacokinetics under Actions).
Diabetic Peripheral Neuropathic Pain: No dosage adjustment is recommended for elderly patients solely on the basis of age. However, caution should be exercised when treating the elderly (see Pharmacology: Pharmacokinetics under Actions).
Generalized Anxiety Disorder (GAD): CYMBALTA should be initiated at a dose of 30 mg once daily for 2 weeks before considering an increase to the target dose of 60 mg. Thereafter, patients may benefit from doses above 60 mg once daily. The maximum dose studied is 120 mg per day.
Children and adolescents: CYMBALTA is not indicated for use in patients under 18 years of age (see Precautions).
Discontinuation of treatment: Abrupt discontinuation should be avoided. When stopping treatment with CYMBALTA the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see Precautions and Adverse Reactions). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.